170 related articles for article (PubMed ID: 23647650)
1. A novel quinoline derivative that inhibits mycobacterial FtsZ.
Mathew B; Ross L; Reynolds RC
Tuberculosis (Edinb); 2013 Jul; 93(4):398-400. PubMed ID: 23647650
[TBL] [Abstract][Full Text] [Related]
2. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity.
Lin Y; Zhang H; Zhu N; Wang X; Han Y; Chen M; Jiang J; Si S
Tuberculosis (Edinb); 2018 May; 110():79-85. PubMed ID: 29779778
[TBL] [Abstract][Full Text] [Related]
3. Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents.
Kumar K; Awasthi D; Lee SY; Zanardi I; Ruzsicska B; Knudson S; Tonge PJ; Slayden RA; Ojima I
J Med Chem; 2011 Jan; 54(1):374-81. PubMed ID: 21126020
[TBL] [Abstract][Full Text] [Related]
4. Screening and Development of New Inhibitors of FtsZ from M. Tuberculosis.
Mathew B; Hobrath JV; Ross L; Connelly MC; Lofton H; Rajagopalan M; Guy RK; Reynolds RC
PLoS One; 2016; 11(10):e0164100. PubMed ID: 27768711
[TBL] [Abstract][Full Text] [Related]
5. A new 2-carbamoyl pteridine that inhibits mycobacterial FtsZ.
Reynolds RC; Srivastava S; Ross LJ; Suling WJ; White EL
Bioorg Med Chem Lett; 2004 Jun; 14(12):3161-4. PubMed ID: 15149666
[TBL] [Abstract][Full Text] [Related]
6. Identification of anti-tuberculosis agents that target the cell-division protein FtsZ.
Lin Y; Zhu N; Han Y; Jiang J; Si S
J Antibiot (Tokyo); 2014 Sep; 67(9):671-6. PubMed ID: 24984796
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents.
Park B; Awasthi D; Chowdhury SR; Melief EH; Kumar K; Knudson SE; Slayden RA; Ojima I
Bioorg Med Chem; 2014 May; 22(9):2602-12. PubMed ID: 24726304
[TBL] [Abstract][Full Text] [Related]
8. SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents.
Awasthi D; Kumar K; Knudson SE; Slayden RA; Ojima I
J Med Chem; 2013 Dec; 56(23):9756-70. PubMed ID: 24266862
[TBL] [Abstract][Full Text] [Related]
9. Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors.
Mathew B; Srivastava S; Ross LJ; Suling WJ; White EL; Woolhiser LK; Lenaerts AJ; Reynolds RC
Bioorg Med Chem; 2011 Dec; 19(23):7120-8. PubMed ID: 22024272
[TBL] [Abstract][Full Text] [Related]
10. Discovery of anti-TB agents that target the cell-division protein FtsZ.
Kumar K; Awasthi D; Berger WT; Tonge PJ; Slayden RA; Ojima I
Future Med Chem; 2010 Aug; 2(8):1305-23. PubMed ID: 21339840
[TBL] [Abstract][Full Text] [Related]
11. Mycobacterium tuberculosis High-Throughput Screening.
White EL; Tower NA; Rasmussen L
Methods Mol Biol; 2016; 1439():181-95. PubMed ID: 27316996
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics analysis of the effects of GTP, GDP and benzimidazole derivative on structural dynamics of a cell division protein FtsZ from
Hakeem S; Singh I; Sharma P; Uppal A; Khajuria Y; Verma V; Uversky VN; Chandra R
J Biomol Struct Dyn; 2019 Oct; 37(16):4361-4373. PubMed ID: 30466358
[TBL] [Abstract][Full Text] [Related]
13. Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents.
Huang Q; Kirikae F; Kirikae T; Pepe A; Amin A; Respicio L; Slayden RA; Tonge PJ; Ojima I
J Med Chem; 2006 Jan; 49(2):463-6. PubMed ID: 16420032
[TBL] [Abstract][Full Text] [Related]
14. An efficient and facile green synthesis of bisindole methanes as potential Mtb FtsZ inhibitors.
Khadkikar P; Goud NS; Mohammed A; Ramamoorthy G; Ananthathatmula R; Doble M; Rizvi A; Banerjee S; Ravi A; Alvala M
Chem Biol Drug Des; 2018 Dec; 92(6):1933-1939. PubMed ID: 30003661
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel class of quinoline-oxadiazole hybrids as anti-tuberculosis agents.
Jain PP; Degani MS; Raju A; Anantram A; Seervi M; Sathaye S; Ray M; Rajan MGR
Bioorg Med Chem Lett; 2016 Jan; 26(2):645-649. PubMed ID: 26675440
[TBL] [Abstract][Full Text] [Related]
16. Identification and synthesis of novel inhibitors of mycobacterium ATP synthase.
Surase YB; Samby K; Amale SR; Sood R; Purnapatre KP; Pareek PK; Das B; Nanda K; Kumar S; Verma AK
Bioorg Med Chem Lett; 2017 Aug; 27(15):3454-3459. PubMed ID: 28587823
[TBL] [Abstract][Full Text] [Related]
17. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro antitubercular activity of a series of quinoline derivatives.
de Souza MV; Pais KC; Kaiser CR; Peralta MA; de L Ferreira M; Lourenço MC
Bioorg Med Chem; 2009 Feb; 17(4):1474-80. PubMed ID: 19188070
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis.
Upadhayaya RS; Kulkarni GM; Vasireddy NR; Vandavasi JK; Dixit SS; Sharma V; Chattopadhyaya J
Bioorg Med Chem; 2009 Jul; 17(13):4681-92. PubMed ID: 19457676
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.
Lilienkampf A; Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP
J Med Chem; 2009 Apr; 52(7):2109-18. PubMed ID: 19271749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
